Michael Robinson 5  CROSS REFERENCE TO RELATED APPLICATIONS This application claims priority to and the benefit of U.S. Provisional Patent Application Nos. 61/915,186 and 61/915,209, each filed December 12, 2013, the disclosures of which are hereby incorporated by reference in their entireties. BACKGROUND OF THE INVENTION 10  1. Field of the Invention The present invention relates to novel compounds capable of modulating, regulating and/or inhibiting tyrosine kinase signal transduction. The present invention is also directed to methods of regulating, modulating or inhibiting tyrosine kinases, whether of the receptor or non- receptor class, for the prevention and/or treatment of disorders related to unregulated tyrosine 15  kinase signal transduction, including cell growth, metabolic, and blood vessel proliferative

disorders.

2. Description of the Related Art

Protein tyrosine kinases (PTKs) comprise a large and diverse class of proteins having enzymatic activity. The PTKs play an important role in the control of cell growth and

20  differentiation.

For example, receptor tyrosine kinase mediated signal transduction is initiated by extracellular interaction with a specific growth factor (ligand), followed by receptor

dimerization, transient stimulation of the intrinsic protein tyrosine kinase activity and

phosphorylation. Binding sites are thereby created for intracellular signal transduction molecules 25  and lead to the formation of complexes with a spectrum of cytoplasmic signaling molecules that facilitate the appropriate cellular response (e.g., cell division, metabolic homeostasis, and responses to the extracellular microenvironment).  

  With respect to receptor tyrosine kinases, it has been shown also that tyrosine

phosphorylation sites function as high-affinity binding sites for SH2 (src homology) domains of signaling molecules. Several intracellular substrate proteins that associate with receptor tyrosine kinases (RTKs) have been identified. They may be divided into two principal groups: (1) 5  substrates which have a catalytic domain; and (2) substrates which lack such domain but serve as adapters and associate with catalytically active molecules. The specificity of the interactions between receptors or proteins and SH2 domains of their substrates is determined by the amino acid residues immediately surrounding the phosphorylated tyrosine residue. Differences in the binding affinities between SH2 domains and the amino acid sequences surrounding the

10  phosphotyrosine residues on particular receptors are consistent with the observed differences in their substrate phosphorylation profiles. These observations suggest that the function of each receptor tyrosine kinase is determined not only by its pattern of expression and ligand availability but also by the array of downstream signal transduction pathways that are activated by a particular receptor. Thus, phosphorylation provides an important regulatory step which 15  determines the selectivity of signaling pathways recruited by specific growth factor receptors, as well as differentiation factor receptors. Aberrant expression or mutations in the PTKs have been shown to lead to either uncontrolled cell proliferation (e.g. malignant tumor growth) or to defects in key developmental processes. Consequently, the biomedical community has expended significant resources to 20  discover the specific biological role of members of the PTK family, their function in

differentiation processes, their involvement in tumorigenesis and in other diseases, the biochemical mechanisms underlying their signal transduction pathways activated upon ligand stimulation and the development of novel drugs. Tyrosine kinases can be of the receptor-type (having extracellular, transmembrane and 25  intracellular domains) or the non-receptor type (being wholly intracellular). The receptor-type tyrosine kinases (RTKs) comprise a large family of transmembrane receptors with diverse biological activities. The intrinsic function of RTKs is activated upon ligand binding, which results in phosphorylation of the receptor and multiple cellular substrates, and subsequently in a variety of cellular responses. The non-receptor tyrosine kinases represent 30  a collection of cellular enzymes which lack extracellular and transmembrane sequences. A more

2 

  detailed discussion of receptor and non-receptor tyrosine kinases is provided in Cowan-Jacob Cell Mol. Life Sci., 2006, 63, 2608-2625 which is incorporated herein by reference. There are a number of examples where RTK kinases, have been found to be involved in cellular signaling pathways leading to pathological conditions, including exudative age-related 5  macular degeneration (Ni et al. Opthalmologica 2009 223 401-410; Chappelow et al. Drugs 2008 68 1029-1036), diabetic retinopathy (Zhang et al., Int. J. Biochem. Cell Biol. 2009 41 2368- 2371), cancer (Aora et al. J. Path. Exp. Ther. 2006, 315, 971), psoriasis (Heidenreich et al Drug News Perspective 2008 21 97-105) and rosacea (Smith, J. R., V. B. Lanier, et al. Br J

Ophthalmol 2007, 91(2): 226-229). In ophthalmic diseases such as exudative age-related 10  macular degeneration and diabetic retinopathy aberrant activation of VEGF receptors can lead to abnormal blood vessel growth. The importance of VEGFR signaling in the exudative age-related macular degeneration disease process is evident by the clinical success of multiple anti-VEGF targeting agents including Lucentis ^® , Avastin ^® , and EYLEA ^TM (Barakat et al., Expert Opin. Investig. Drugs 2009, 18, 637). Recently it has been suggested that inhibition of multiple RTK 15  signaling pathways may provide a greater therapeutic effect than targeting a single RTK

signaling pathway. For example in neovascular ocular disorders such as exudative age-related macular degeneration and diabetic retinopathy the inhibition of both VEGFR and PDGFRβ may provide a greater therapeutic effect by causing regression of existing neovascular blood vessels present in the disease (Adamis et al., Am. J. Pathol. 2006 168 2036-2053). In cancer inhibition 20  of multiple RTK signaling pathways has been suggested to have a greater effect than inhibiting a single RTK pathway (DePinho et al., Science 2007 318 287-290; Bergers et al. J. Clin Invest. 2003 111 1287-1295). WO 2013/062843 A1 refers to pyridine-sulfoximines as tyrosine kinase inhibitors. WO 2008/061236 A2 refers to sulfoximine-nicotine derivatives as kinase inhibitors and 25  their preparation, pharmaceutical compositions and use in the treatment of proliferative diseases. The identification of effective small compounds which specifically inhibit signal transduction by modulating the activity of receptor and non-receptor tyrosine kinases to regulate and modulate abnormal or inappropriate cell proliferation is therefore desirable and one object of this invention. 3 

  The above references are hereby incorporated by reference in their entirety for the purpose of disclosing starting materials and methods for the preparation thereof, screens and assays to determine a claimed compound’s ability to modulate, regulate and/or inhibit cell proliferation, indications which are treatable with said compounds, formulations and routes of 5  administration, effective dosages, etc. BRIEF SUMMARY OF THE INVENTION The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting tyrosine kinase signal transduction by blocking the VEGF and/or PDGF receptors. Such compounds are useful for the treatment of diseases related to unregulated 10  tyrosine kinase signal transduction, including vascular proliferative disorders such as diabetic retinopathy, age-related macular degeneration and retinopathy of prematurity.

In one illustrative embodiment, the compounds of the present invention have the following general formula I:

15 

  R ² is hydrogen or NH ₂

X =

5  Ar ¹ is an aryl, i.e. a carbocyclic aryl or a heteroaryl group, R ³ is hydrogen or lower alkyl, or

10  R ⁴ is hydrogen, lower alkyl, (CH ₂ ) _n COOR ⁶ or (CH ₂ ) _n COR ⁷ , R ⁵ is hydrogen or lower alkyl, R ⁶ is hydrogen or lower alkyl,

15 

R ⁷ is an amine, e.g a substituted amine, which may be selected from the group consisting of

  and n is 0, or an integer of from 1 to 6 and further including prodrugs, pharmaceutically acceptable salts, racemic mixtures and enantiomers thereof. Preferably, in formula I, X is–NH-C(O)-. 5  Preferably, in formula I, Y is CH. Preferably, in formula I, Ar ¹ is elected from the group consisting of phenyl and furanyl, e.g.lower alkyl and/or halo-substituted phenyl and furanyl. Most preferably Ar ¹ is selected from the group consisting of 3-methyl-2-furanyl and 2-fluoro-5-methylphenyl. Preferably, in formula I, R ² is H. 10  Preferably, in formula I, R ³ is selected from the group consisting of

wherein R ⁴ and R ⁵ are as defined above. More preferably in formula I, R ³ is selected from the group consisting of 15  -C(O)N(R ⁴ )(R ⁵ ) wherein R ⁴ and R ⁵ are as defined above. In another illustrative embodiment, the compounds of the present invention have the following general formula II:

II wherein

R ¹ is hydrogen or NH ₂ 5  R ² is hydrogen or NH ₂ X is

Ar ¹ is an aryl group, i.e. a carbocyclic aryl group or heteroaryl group, further including 10  prodrugs, pharmaceutically acceptable salts, racemic mixtures and enantiomers thereof. Said carbocyclic aryl or heteroaryl group may be optionally substituted with one or more alkoxy, halogen, trihaloalkyl (e.g., trifluoromethyl), or lower alkyl radicals. Preferably, in formula II, X is–NHC(O)- or –C(O)NH- Preferably, in formula II, Y is CH. 15  Preferably, in formula II, Ar ¹ is selected from the group consisting of phenyl, oxazoyl and furanyl and.lower alkyl, alkyloxy and/or halo-substituted phenyl, oxazoyl and furanyl. Most preferably in formula II, Ar ¹ is selected from the group consisting of 3-methylfuranyl, 2-fluoro 5-methylphenyl, 4-chloro 5-t-butylphenyl, 3-methoxyphenyl and 5—butyloxazoyl.  

  Preferably, in formula II, R ² is H. Most preferably, said compounds of formulae I and II are selected from the group consisting of: tert-butyl 1-({[5-({3-[(3-methyl-2-furoyl)amino]phenyl}ethynyl)pyridin- 3-yl]carbonyl}imino)-1 λ ⁴ ,4-thiazinane-4-carboxylate 1-oxide

5  1-({[5-({3-[(3-methyl-2-furoyl)amino]phenyl}ethynyl)pyridin- 3-yl]carbonyl}imino)-1 λ ⁴ ,4- thiazinane-4-carboxamide 1-oxide

1-({[5-({3-[(3-methyl-2-furoyl)amino]phenyl}ethynyl)pyridin- 3-yl]carbonyl}imino)-1 λ ⁴ ,4- thiazinane-4-carboxamide 1-oxide

ethyl 3-({[1 -({[5-({3-[(3-methyl-2-furoyl)amino]phenyl}ethynyl)pyridin-3 -yl]carbonyl}imino)- 10  1-oxido-1 λ ⁴ ,4-thiazinan-4-yl]carbonyl}amino)propanoate

ethyl 4-({[1-({[5-({3-[(3-methyl-2-furoyl)amino]phenyl}ethynyl)pyr idin-3-yl]carbonyl}imino)- 1-oxido-1 λ ⁴ ,4-thiazinan-4-yl]carbonyl}amino)butanoate

3-({[1-({[5-({3-[(3-methyl-2-furoyl)amino]phenyl}ethynyl)pyr idin-3-yl]carbonyl}imino)-1- oxido-1 λ ⁴ ,4-thiazinan-4-yl]carbonyl}amino)propanoic acid

15  4-({[1-({[5-({3-[(3-methyl-2-furoyl)amino]phenyl}ethynyl)pyr idin-3-yl]carbonyl}imino)-1- oxido-1 λ ⁴ ,4-thiazinan-4-yl]carbonyl}amino)butanoic acid

N-[3-(3-hydroxypyrrolidin-1-yl)-3-oxopropyl]-1-({[5-({3-[(3- methyl-2- furoyl)amino]phenyl}ethynyl)pyridin-3-yl]carbonyl}imino)-1 λ ⁴ ,4-thiazinane-4-carboxamide 1- oxide

20  N-[4-(3-hydroxypyrrolidin-1-yl)-4-oxobutyl]-1-({[5-({3-[(3-m ethyl-2- furoyl)amino]phenyl}ethynyl)pyridin-3-yl]carbonyl}imino)-1 λ ⁴ ,4-thiazinane-4-carboxamide 1- oxide

N-{4-[(2,3-dihydroxypropyl)amino]-4-oxobutyl}-1-({[5-({3-[(3 -methyl-2- furoyl)amino]phenyl}ethynyl)pyridin-3-yl]carbonyl}imino)-1 λ ⁴ ,4-thiazinane-4-carboxamide 1- 25  oxide

ethyl ({[1-({[5-({3-[(3-methyl-2-furoyl)amino]phenyl}ethynyl)pyrid in-3-yl]carbonyl}imino)-1- oxido-1 λ ⁴ ,4-thiazinan-4-yl]carbonyl}amino)acetate

({[1-({[5-({3-[(3-methyl-2-furoyl)amino]phenyl}ethynyl)pyrid in-3-yl]carbonyl}imino)-1-oxido- 1 λ ⁴ ,4-thiazinan-4-yl]carbonyl}amino)acetic acid

30  tert-butyl 1-({[6-amino-5-({3-[(3-methyl-2-furoyl)amino]phenyl}ethynyl) pyridin-3- yl]carbonyl}imino)-1 λ ⁴ ,4-thiazinane-4-carboxylate 1-oxide  

  6-amino-5-({3-[(3-methyl-2-furoyl)amino]phenyl}ethynyl)-N-(1 -oxido-1 λ ⁴ ,4-thiazinan-1- ylidene)nicotinamide

1-({[6-amino-5-({3-[(3-methyl-2-furoyl)amino]phenyl}ethynyl) pyridin-3-yl]carbonyl}imino)-1 λ ⁴ ,4-thiazinane-4-carboxamide 1-oxide

5  tert-butyl 1-({[6-amino-5-({3-[(2-fluoro-5-methylbenzoyl)amino]phenyl}e thynyl)pyridin-3- yl]carbonyl}imino)-1 λ ⁴ ,4-thiazinane-4-carboxylate 1-oxide

6-amino-5-({3-[(2-fluoro-5-methylbenzoyl)amino]phenyl}ethyny l)-N-(1-oxido-1 λ ⁴ ,4-thiazinan- 1-ylidene)nicotinamide

1-({[6-amino-5-({3-[(2-fluoro-5-methylbenzoyl)amino]phenyl}e thynyl)pyridin-3- 10  yl]carbonyl}imino)-1 λ ⁴ ,4-thiazinane-4-carboxamide 1-oxide 5-({3-[(3-methyl-2-furoyl)amino]phenyl}ethynyl)-N-(4-oxido-1 ,4λ ⁴ -oxathian-4- ylidene)nicotinamide,

6-amino-5-({3-[(3-methyl-2-furoyl)amino]phenyl}ethynyl)-N-(4 -oxido-1,4 λ ⁴ -oxathian-4- ylidene)nicotinamide,

15  6-amino-5-({3-[(2-fluoro-5-methylbenzoyl)amino]phenyl}ethyny l)-N-(4-oxido-1,4 λ ⁴ -oxathian- 4-ylidene)nicotinamide,

6-amino-5-[(3-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phen yl)ethynyl]-N-(4-oxido-1,4 λ ⁴ - oxathian-4-ylidene)nicotinamide,

6-amino-5-{[3-({[4-chloro-3-(trifluoromethyl)phenyl]amino}ca rbonyl)phenyl]ethynyl}-N-(4- 20  oxido-1,4 λ ⁴ -oxathian-4-ylidene)nicotinamide,

6-amino-5-[(3-{[(5-tert-butylisoxazol-3-yl)amino]carbonyl}ph enyl)ethynyl]-N-(4-oxido-1,4 λ ⁴ - oxathian-4-ylidene)nicotinamide and

6-amino-5-[(3-{[(3-methoxyphenyl)amino]carbonyl}phenyl)ethyn yl]-N-(4-oxido-1,4 λ ⁴ - oxathian-4-ylidene)nicotinamide.

25  Compounds of formulae I and II are useful as kinase inhibitors. As such, compounds of formula I will be useful for treating diseases related to unregulated tyrosine kinase signal transduction, for example, cancer, blood vessel proliferative disorders, fibrotic disorders, and neurodegenerative diseases. In particular, the compounds of the present invention are useful for treatment of mesangial cell proliferative disorders and metabolic diseases, pterigium, arthritis, 30  restenosis, hepatic cirrhosis, atherosclerosis, psoriasis, rosacea, diabetis mellitus, wound healing,  

  and neurodegenerative diseases and preferably ophthalmic diseases, i.e. diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, pterygia, blepharoconjunctivitis, chronic allergic conjunctivitis, recurrent episcleritis, keratoconjunctivitis sicca. In addition the following dermatological indications may be treated with the compounds of this invention: sun 5  burn , eczema, psoriasis, contact dermatitis. DETAILED DESCRIPTION OF THE INVENTION The present invention is further directed to pharmaceutical compositions comprising a pharmaceutically effective amount of one or more of the above-described compounds and a pharmaceutically acceptable carrier or excipient, wherein said compositions are effective for 10  treating the above diseases and conditions; especially ophthalmic diseases and conditions. Such a composition is believed to modulate signal transduction by a tyrosine kinase, either by inhibition of catalytic activity, affinity to ATP or ability to interact with a substrate. More particularly, the compositions of the present invention may be included in methods for treating diseases comprising proliferation, fibrotic or metabolic disorders, for example 15  cancer, fibrosis, psoriasis, rosacea, atherosclerosis, arthritis, and other disorders related to

abnormal vasculogenesis and/or angiogenesis, such as exudative age related macular

degeneration and diabetic retinopathy. The compositions of the present invention are also useful in treating pterygia, blepharoconjunctivitis, chronic allergic conjunctivitis, recurrent episcleritis, keratoconjunctivitis sicca. In addition the following dermatological indications may be treated: 20  sun burn, eczema, psoriasis contact dermatitis

Most preferably, the compounds of the present invention are useful an ophthalmic disease, wherein said ophthalmic disease is selected from the group consisting of pterygia, hyperemia related to an actively inflamed pterygia, recurrent pterygia following excisional surgery, prophylactic therapy to prevent recurrent pterygia post-excision, progressive pterygia 25  approaching the visual axis, chronic low grade hyperemia associated with pterygia, corneal neovascularization, neovascular glaucoma, iris neovascularization, chronic allergic conjunctivitis, ocular rosacea, blepharoconjunctivitis, recurrent episcleritis, keratoconjunctivitis sicca, ocular graft vs host disease, diabetic retinopathy, diabetic macular edema, proliferative diabetic retinopathy, exudative or neovascular age-related macular degeneration, high-risk eyes  

  (i.e. fellow eyes have neovascular age-related macular degeneratuon) with dry age-related macular degeneration, neovascular disease associated with retinal vein occlusion, neovascular disease (including choroidal neovascularization) associated with the following: pathologic myopia, pseudoxanthoma elasticum, optic nerve drusen, traumatic choroidal rupture, idiopathic 5  etiologies, presumed ocular histoplasmosis syndrome, and retinopathy of prematurity.

The following defined terms are used throughout this specification:

“BOP” refers to benzotriazol-1-yloxytris(dimethylamino)phosphoniumhexafluoro phnosphate “BOC” refers to ditertiarybutyldicarbonate “DCM” refers to dichloromethane

10  “DIPEA” refers to diisopropylethylamine

“DMAP” refers to dimethylformamide

“DMF” refers to dimethylformamide

“EDCI” refers to N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide

“PDGF” refers to platelet derived growth factor.

15  “PDGFR” refers to platelet derived growth factor receptor.

“Ph” refers to phenyl

“PTK” refers to protein tyrosine kinase

“RT” refers to room temperature

“RTK” refers to receptor tyrosine kinase

20  “THF” refers to tetrahydrofuran

“VEGF” refers to vascular endothelial growth factor

“VEGFR” refers to vascular endothelial growth factor receptor “Hydrocarbyl" refers to a hydrocarbon radical having only carbon and hydrogen atoms. Preferably, the hydrocarbyl radical has from 1 to 20 carbon atoms, more preferably from 1 to 12 25  carbon atoms and most preferably from 1 to 7 carbon atoms.  

  "Substituted hydrocarbyl" refers to a hydrocarbyl radical wherein one or more, but not all, of the hydrogen and/or the carbon atoms are replaced by a halogen, nitrogen, oxygen, sulfur or phosphorus atom or a radical including a halo, nitrogen, oxygen, sulfur or phosphorus atom, e.g. fluoro, chloro, cyano, nitro, dialkylamino, hydroxyl, phosphate, thiol, etc. 5  The compounds of Formulae I and II can form salts which are also within the scope of this

invention. Reference to a compound of Formula I or II herein is understood to include reference to salts thereof, unless otherwise indicated. The term "salt(s)", as employed herein,

denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts

10  formed with inorganic and/or organic bases. In addition, when a compound of Formula I or II contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term "salt(s)" as used herein. Pharmaceutically

acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other 15  salts are also useful. Salts of the compounds of the Formulae I and II may be formed, for

example, by reacting a compound of Formula I or II with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.

Exemplary acid addition salts include acetates, ascorbates, benzoates,

20  benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates,

camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates,

propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates

(also known as tosylates,) and the like. Additionally, acids which are generally considered 25  suitable for the formation of pharmaceutically useful salts from basic pharmaceutical

compounds are discussed, for example, by P. Stahl et al, Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33 201-217; Anderson et al, The Practice of Medicinal Chemistry 30  (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration,  

  Washington, D.C. on their website). These disclosures are incorporated herein by

reference thereto.

Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium

5  salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines,

t-butyl amines, and salts with amino acids such as arginine, lysine and the like. Basic

nitrogen-containing groups may be quarternized with agents such as lower alkyl halides

(e.g. methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g.

dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g. decyl, lauryl, and stearyl 10  chlorides, bromides and iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and

others. All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention. Prodrugs and solvates of the compounds of the invention are also contemplated

15  herein. A discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press. The term“prodrug” means a compound (e.g, a drug precursor) that is transformed in vivo to yield a compound of Formula (I) or a pharmaceutically acceptable 20  salt, hydrate or solvate of the compound. The transformation may occur by various

mechanisms (e.g., by metabolic or chemical processes), such as, for example, through hydrolysis in blood. A discussion of the use of prodrugs is provided by T. Higuchi and W.

25 Stella,“Pro-drugs as Novel Delivery Systems,” Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American

25  Pharmaceutical Association and Pergamon Press, 1987. "Alkyl” refers to a straight-chain, branched or cyclic saturated aliphatic hydrocarbon.

Preferably, the alkyl group has 1 to 12 carbons. More preferably, it is a lower alkyl of from 1 to 7 carbons, most preferably 1 to 4 carbons. Typical alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl and the like. The alkyl group may be  

  optionally substituted with one or more substituents are selected from the group consisting of hydroxyl, cyano, alkoxy, =O, =S, NO ₂ , halogen, dimethyl amino, and SH.

“Alkoxy” refers to O-alkyl. "Aryl” refers to an aromatic group which has at least one ring having a conjugated pi 5  electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups. The aryl group may be optionally substituted with one or more substituents selected from the group consisting of halogen, trihalomethyl (e.g., trifluoromethyl), hydroxyl, SH, OH, NO ₂ , amine, thioether, cyano, alkoxy, alkyl, and amino.

“Carbocyclic aryl” refers to an aryl group wherein the ring atoms are carbon

10  “Heteroaryl" or“heterocyclic aryl” refers to an aryl group having from 1 to 3 heteroatoms as ring atoms, the remainder of the ring atoms being carbon. Heteroatoms include oxygen, sulfur, and nitrogen. Thus, heteroaryl groups include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the like.

“Heterocyclic” refers to cyclic group having at least one enchained heteroatom and 15  includes aromatic and non-aromatic cyclic groups. Specific examples of the compounds of the invention and the structures of said compounds are given in the table, below. However, the invention is not limited to the following compounds and structures.

20 

  ⁾

P

( ^A

S

7 _U

3 ₅

1 ^{9 - 4} - - - - - -

  1 ⁵

  ⁾

P

( ^A

S

7 _U

3 ₅

1 ⁹

3- ₃ - ₃ ^{- ic}

  1 ⁶

  ⁾

P

( ^A

S

7 _U

3 ₅

1 ^{9 -} - - ^- _-3 ⁴ ₃ - - ⁴ - ₃ - - - - ⁴ _{-3 e}

  1 ⁷

  ⁾

P

( ^A

S

U

5 ⁷

3

1 ⁹

3- ₃ - - - ⁴ - ₃ ⁴ -

  1 ⁸

  ⁾

P

( ^A

S

7 _U

3 ₅

1 ^{9 p} ) ^{- p}

l - -

  1 ⁹

  ⁾

P

( ^A

S

7 _U

3 ₅

1 ^{9 -} e l - ^{- y} ₃ -

  2 ⁰

  ⁾

P

( ^A

S

7 _U

5

9 ₃

1 ^{l -}

  2 ¹

  Routes to compounds of formula I are illustrated by but not limited to the schemes provided below:

Scheme 1

5 

22 

Scheme 2

Routes to compounds of formula II are illustrated by but not limited to the schemes provided 5  below:

23 

  Scheme 3

5 

Scheme 4

10  24   

The invention is further illustrated by the following nonlimiting Examples.

Preparation 1

tert-Butyl thiomorpholine-4-carb 5  To a solution of thiomorpholine (4.84 mL, 50 mmol, 1 eq) in DCM (200 mL) was added Et ₃ N (14.6 mL, 2.1 eq) and di-tert-butyldicarbonate (12.0 g, 1.1 eq) with stirring under nitrogen atmosphere. The resulting clear solution was stirred at RT for an overnight. The reaction solution was washed with H ₂ O (1X), aqueous NH ₄ Cl (1X), brine (1X) and dried over anhydrous MgSO ₄ . The organic solution was filtered through a pad of celite and the filtrate concentrated. The white 10  solid residue was treated with EtOAc-hexane (1:25) with stirring and then cooled in fridge for 30 min. The white solid which formed was collected to give the title compound as a white crystalline solid (10.1 g, quantitative). ¹ H NMR (DMSO-d ₆ ) δ: 3.54 - 3.59 (m, 4H), 2.48 - 2.54 (m, 4H), 1.40 (s, 9H) Preparation 2

15  tert-Butyl thiomorpholine-4-car - In a 250 mL round-bottom flask equipped with a magnetic stirrer were placed powdered sodium metaperiodate (5.68 g, 1.05 eq) and water (50 mL). The mixture was stirred at RT first and then cooled to 0 °C, followed by the addition of tert-butyl thiomorpholine-4-carboxylate 20  (5.08 g, 25 mmol, 1 eq). Then to this mixture was added dixane (30 mL) and MeOH (40 mL).

The reaction mixture was stirred at 0 ^o C for 5.5 hours. It was then filtered through a Buchner funnel, the white solid was washed with CHCl ₃ (3X50 mL), and the resulting water-chloroform filtrate was transferred into a separation funnel. The lower chloroform was removed and the aqueous layer was extracted with CHCl ₃ (3X 150 mL). The organic phases were combined and 25 

dried over anhydrous Na ₂ SO ₄ overnight. The upper clear layer was then decanted and

concentrated to give the title compound as white solid (5.41 g, 99%). ¹ H NMR (DMSO-d ₆ ) δ: 3.81 (d, J = 13.4 Hz, 2H), 3.60 (br. s., 2H), 2.76 - 2.84 (m, 2H), 2.65 - 2.71 (m, 2H), 1.41 (s, 9H) Preparation 3

5  tert-Butyl 1-imino-1 λ ⁴ ,4-thiazin - - - de Trifluoroacetamide (5.82 g, 2 eq), magnesium oxide (4.05 g, 4 eq), and rhodium(II) acetate dimer (330 mg, 0.03 eq) were placed in a 250 mL round bottom flask. Dichloromethane (70 mL) under a nitrogen atmosphere was then added with stirring, followed by the addition of 10  tert-butyl thiomorpholine-4-carboxylate 1-oxide (5.41 g, 1 eq) and diacetoxyiodobenzene (12.1 g, 1.5 eq). The reaction mixture was stirred at RT overnight. Then it was filtered through a pad of celite and silica gel, washed with DCM first then with EtOAc. The filtrate was concentrated and the resulting oily residue was taken up in MeOH (250 mL), to which was added potassium carbonate (17.3 g, 5 eq). The reaction mixture was stirred at RT for 2 hours and filtered through 15  a pad of celite and silica gel and washed with MeOH. The filtrate was concentrated under

reduced pressure and the resulting lightly brown oily residue was treated with EtOAc with stirring at RT. The mixture was filtered again and the filtrate was concentrated yielding the title compound as a crude light brown soft solid which was used directly without further purification. 1H NMR (DMSO-d ₆ ) δ: 3.84 (ddd, J = 14.4, 4.5, 4.4 Hz, 2H), 3.79 (s, 1H), 3.49 - 3.58 (m, 2H), 20  2.96 (t, J = 4.3 Hz, 4H), 1.41 (s, 9H)

26 

Example 1: O CH ₃

tert-Butyl 1-({[5-({3-[(3-methyl-2-furoyl)amino]phenyl}ethynyl)pyridin- 3- 5  yl]carbonyl}imino)-1 λ ⁴ ,4-thiazinane-4-carboxylate 1-oxide A stirring solution of tert-butyl 1-imino-1 λ ⁴ ,4-thiazinane-4-carboxylate 1-oxide, (468 mg, 2 mmol, 1 eq) and 5-{3-[(3-methyl-furan-2-carbonyl)-amino]-phenylethynyl}-nico tinic acid, (730 mg, 1.05 eq) in DMF (7 mL) under nitrogen atmosphere was treated with DIPEA (0.70 mL, 2 eq) and BOP (1.0 g, 1.1 eq). The resulting reaction mixture was stirred at RT for 15 10  minutes and then diluted with EtOAc. The mixture was washed sequentially with saturated aq NaHCO ₃ (2X), aq NH ₄ Cl (1X), and brine (1X), and then dried with anhydrous Na ₂ SO ₄ and concentrated. The residue was purified by gradient chromatography (EtOAc-Hex from 1:3 to 1: 1) to give the title compound as white foam (820 mg, 73%). ¹ H NMR (DMSO-d ₆ ) δ: 10.21 (s, 1H), 9.11 (d, J = 2.0 Hz, 1H), 8.93 (d, J = 2.0 Hz, 1H), 8.44 (t, J = 2.1 Hz, 1H), 8.14 (t, J = 1.7 15  Hz, 1H), 7.77 - 7.83 (m, 2H), 7.39 - 7.44 (m, 1H), 7.34 (dt, J = 7.8, 1.0 Hz, 1H), 6.61 (d, J = 1.2 Hz, 1H), 3.99 - 4.10 (m, 2H), 3.80 - 3.86 (m, 2H), 3.55 - 3.67 (m, 4H), 2.35 (s, 3H), 1.43 (s, 9H) Example 2:

20  5-({3-[(3-Methyl-2-furoyl)amino]phenyl}ethynyl)-N-(1-oxido-1 λ ⁴ ,4-thiazinan-1- ylidene)nicotinamide 27 

A 0 ^o C solution of tert-butyl 1-({[5-({3-[(3-methyl-2- furoyl)amino]phenyl}ethynyl)pyridin-3-yl]carbonyl}imino)-1 λ ⁴ ,4-thiazinane-4-carboxylate 1- oxide (260 mg, 0.46 mmol, 1 eq) in DCM (2.0 mL) was treated dropwise with trifluoroacetic acid (0.72 mL) and the reaction was stirred at RT for 3 hours. The reaction mixture was diluted 5  with chloroform, washed with saturated aq NaHCO ₃ (1X), brine (1X), and dried with anhydrous Na ₂ SO ₄ overnight. The upper clear layer was decanted, concentrated, and the oily residue was purified by column chromatography (MeOH-CHCl ₃ 1:100 to 1:25) to give the title compound as white solid (172 mg, 81%). ¹ H NMR (DMSO-d ₆ ) δ: 10.21 (s, 1H), 9.11 (d, J = 2.0 Hz, 1H), 8.93 (d, J = 2.1 Hz, 1H), 8.42 (t, J = 2.0 Hz, 1H), 8.13 (t, J = 1.7 Hz, 1H), 7.78 - 7.82 (m, 2H), 7.39 - 10  7.43 (m, 1H), 7.34 (dt, J = 7.6, 1.2 Hz, 1H), 6.61 (d, J = 1.5 Hz, 1H), 3.75 (dt, J = 13.9, 2.6 Hz, 2H), 3.33 - 3.40 (m, 2H), 3.24 - 3.30 (m, 2H), 3.00 - 3.09 (m, 2H), 2.35 (s, 3H). Example 3

1-({[5-({3-[(3-Methy - - - - rbonyl}imino)-1 λ ⁴ ,4- 15  thiazinane-4-carboxamide 1-oxide In a manner similar to that described in Example 5, 5-({3-[(3-methyl-2- furoyl)amino]phenyl}ethynyl)-N-(1-oxido-1 λ ⁴ ,4-thiazinan-1-ylidene)nicotinamide and isocyanatotrimethylsilane were converted to the title compound.

1H NMR (DMSO-d ₆ ) δ: 10.21 (s, 1H), 9.12 (d, J = 2.0 Hz, 1H), 8.93 (d, J = 2.1 Hz, 1H), 8.44 (t, 20  J = 2.1 Hz, 1H), 8.13 (t, J = 1.6 Hz, 1H), 7.82 (d, J = 1.5 Hz, 1H), 7.78 - 7.81 (m, 1H), 7.39 - 7.43 (m, 1H), 7.34 (dt, J = 7.7, 1.1 Hz, 1H), 6.61 (d, J = 1.5 Hz, 1H), 6.35 (s, 2H), 4.05 - 4.12 (m, 2H), 3.77 - 3.83 (m, 2H), 3.56 - 3.64 (m, 2H), 3.46 - 3.53 (m, 2H), 2.35 (s, 3H)

28 

  Example 4

Ethyl 3-({[1-( - - - - - - - yl]carbonyl}imino)-1-oxido-1 λ ⁴ ,4-thiazinan-4-yl]carbonyl}amino)propanoate 5  In a manner similar to that described in Example 5, 5-({3-[(3-methyl-2- furoyl)amino]phenyl}ethynyl)-N-(1-oxido-1 λ ⁴ ,4-thiazinan-1-ylidene)nicotinamide and ethyl 3- isocyanatopropanoate were converted to the title compound.

1H NMR (DMSO-d ₆ ) δ: 10.21 (s, 1H), 9.12 (d, J = 2.0 Hz, 1H), 8.93 (d, J = 2.1 Hz, 1H), 8.44 (t, J = 2.0 Hz, 1H), 8.13 (t, J = 1.7 Hz, 1H), 7.82 (d, J = 1.6 Hz, 1H), 7.78 - 7.81 (m, 1H), 7.39 - 10  7.43 (m, 1H), 7.34 (dt, J = 7.6, 1.1 Hz, 1H), 7.02 (t, J = 5.3 Hz, 1H), 6.61 (d, J = 1.5 Hz, 1H), 4.02 - 4.10 (m, 4H), 3.77 - 3.83 (m, 2H), 3.56 - 3.64 (m, 2H), 3.44 - 3.51 (m, 2H), 3.26 - 3.30 (m, 2H), 2.45 - 2.49 (m, 2H), 2.35 (s, 3H), 1.18 (t, J = 7.1 Hz, 3H) Example 5 O CH ₃

15  Ethyl 4-({[1- - - - - - - - yl]carbonyl}imino)-1-oxido-1 λ ⁴ ,4-thiazinan-4-yl]carbonyl}amino)butanoate To a solution of 5-({3-[(3-methyl-2-furoyl)amino]phenyl}ethynyl)-N-(1-oxido-1 λ ⁴ ,4- thiazinan-1-ylidene)nicotinamide (Example 2) (170 mg, 0.368 mmol, 1 eq) in DMF (2 mL) was added dropwise ethyl 4-isocyanatobutyrate (179 mg, 3 eq) and the reaction was stirred at RT for 29 

3 hours. The reaction was then poured into saturated aq NaHCO ₃ and extracted with EtOAc. The organic layer isolated was then washed with aq NH ₄ Cl (1X), brine (1X), and dried with anhydrous Na ₂ SO ₄ and concentrated. The residue was purified by gradient column

chromatography (EtOAc-Hex 3:1 to 6:1) to give the title compound as white solid (196 mg, 5  86%).

1H NMR (DMSO-d ₆ ) δ: 10.21 (s, 1H), 9.12 (d, J = 2.1 Hz, 1H), 8.93 (d, J = 2.1 Hz, 1H), 8.44 (t, J = 2.0 Hz, 1H), 8.13 (t, J = 1.7 Hz, 1H), 7.82 (d, J = 1.6 Hz, 1H), 7.78 - 7.81 (m, 1H), 7.39 - 7.43 (m, 1H), 7.34 (dt, J = 7.7, 1.2 Hz, 1H), 6.90 (t, J = 5.4 Hz, 1H), 6.61 (d, J = 1.6 Hz, 1H), 4.01 - 4.12 (m, 4H), 3.76 - 3.83 (m, 2H), 3.62 (dd, J = 13.1, 9.4 Hz, 2H), 3.46 - 3.53 (m, 2H), 10  3.04 - 3.09 (m, 2H), 2.35 (s, 3H), 2.31 (t, J = 7.5 Hz, 2H), 1.68 (quin, J = 7.2 Hz, 2H), 1.17 (t, J = 7.1 Hz, 3H) Example 6

3-({[1-({[5-({3-[ - - - - - rbonyl}imino)-1- 15  oxido-1 λ ⁴ ,4-thiazinan-4-yl]carbonyl}amino)propanoic acid In a manner similar to that described in Example 7, ethyl 3-({[1-({[5-({3-[(3-methyl-2- furoyl)amino]phenyl}ethynyl)pyridin-3-yl]carbonyl}imino)-1-o xido-1 λ ⁴ ,4-thiazinan-4- yl]carbonyl}amino)propanoate was converted to the title compound.

1H NMR (DMSO-d ₆ ) δ: 12.09 (br. s., 1H), 10.21 (s, 1H), 9.12 (d, J = 2.0 Hz, 1H), 8.93 (d, J = 2.1 20  Hz, 1H), 8.44 (t, J = 2.0 Hz, 1H), 8.13 (t, J = 1.6 Hz, 1H), 7.77 - 7.83 (m, 2H), 7.39 - 7.43 (m, 1H), 7.34 (d, J = 7.7 Hz, 1H), 7.00 (t, J = 5.0 Hz, 1H), 6.61 (d, J = 1.6 Hz, 1H), 4.04 - 4.11 (m, 2H), 3.76 - 3.83 (m, 2H), 3.56 - 3.64 (m, 2H), 3.44 - 3.52 (m, 2H), 3.23 - 3.29 (m, 2H), 2.40 (t, J = 7.0 Hz, 2H), 2.35 (s, 3H)

30 

Example 7

4-({[1-({[5-({3-[(3-Methyl-2-furoyl)amino]phenyl}ethynyl)pyr idin-3-yl]carbonyl}imino)-1- 5  oxido-1 λ ⁴ ,4-thiazinan-4-yl]carbonyl}amino)butanoic acid A solution of ethyl 4-({[1-({[5-({3-[(3-methyl-2-furoyl)amino]phenyl}ethynyl)pyr idin-3- yl]carbonyl}imino)-1-oxido-1 λ ⁴ ,4-thiazinan-4-yl]carbonyl}amino)butanoate (Example 5) (182 mg, 0.294 mmol, 1 eq) in THF (4 mL) was treatd with 1 N KOH (1.5 mL) dropwise and the reaction was stirred at RT for 3 hours. The reaction was cooled to 0 °C and 2N aq HCl (0.6 mL) 10  was added dropwise. The resulting mixture was partitioned between aq NH ₄ Cl and EtOAc. The organic layer was isolated, washed with brine (1X), and dried over anhydrous Na ₂ SO ₄ . The clear upper solution was decanted, concentrated. The resiude was purified by column chromatography (MeOH-DCM 1:20 to 1:10) to give the title compound as white solid (148 mg, 77%).

1H NMR (DMSO-d ₆ ) δ: 12.00 (br. s., 1H), 10.21 (s, 1H), 9.12 (d, J = 2.1 Hz, 1H), 8.93 (d, J = 2.1 15  Hz, 1H), 8.44 (t, J = 2.0 Hz, 1H), 8.13 (dt, J = 6.8, 1.6 Hz, 1H), 7.78 - 7.83 (m, 2H), 7.39 - 7.44 (m, 1H), 7.34 (dd, J = 7.6, 1.2 Hz, 1H), 6.90 (t, J = 5.3 Hz, 1H), 6.61 (d, J = 1.1 Hz, 1H), 4.05 - 4.13 (m, 2H), 3.77 - 3.84 (m, 2H), 3.57 - 3.65 (m, 2H), 3.45 - 3.52 (m, 2H), 3.03 - 3.09 (m, 2H), 2.35 (s, 3H), 2.23 (t, J = 7.3 Hz, 2H), 1.66 (quin, J = 7.2 Hz, 2H). Example 8

20 

N-[3-(3-Hydroxypyrrolidin-1-yl)-3-oxopropyl]-1-({[5-({3-[ (3-methyl-2- furoyl)amino]phenyl}ethynyl)pyridin-3-yl]carbonyl}imino)-1 λ ⁴ ,4-thiazinane-4- carboxamide 1-oxide In a manner similar to that described in Example 9, 3-({[1-({[5-({3-[(3-methyl-2- 5  furoyl)amino]phenyl}ethynyl)pyridin-3-yl]carbonyl}imino)-1-o xido-1 λ ⁴ ,4-thiazinan-4- yl]carbonyl}amino)propanoic acid and DL-pyrrolidin-3-ol were converted to the title compound. 1H NMR (DMSO-d ₆ ) δ: 10.21 (s, 1H), 9.12 (d, J = 2.0 Hz, 1H), 8.93 (d, J = 2.1 Hz, 1H), 8.44 (t, J = 2.1 Hz, 1H), 8.13 (t, J = 1.6 Hz, 1H), 7.82 (d, J = 1.5 Hz, 1H), 7.78 - 7.81 (m, 1H), 7.39 - 7.43 (m, 1H), 7.34 (dt, J = 7.6, 1.1 Hz, 1H), 6.96 (t, J = 5.3 Hz, 1H), 6.61 (d, J = 1.3 Hz, 1H), 10  4.88 - 4.99 (m, 1H), 4.20 - 4.31 (m, 1H), 4.07 (dd, J = 16.0, 2.8 Hz, 2H), 3.77 - 3.83 (m, 2H), 3.60 (dd, J = 13.9, 9.0 Hz, 2H), 3.36 - 3.52 (m, 4H), 3.21 - 3.29 (m, 4H), 2.37 - 2.46 (m, 2H), 2.35 (s, 3H), 1.72 - 1.96 (m, 2H) Example 9

15  - - - - - - - - - - - - l-2- furoyl)amino]phenyl}ethynyl)pyridin-3-yl]carbonyl}imino)-1 λ ⁴ ,4-thiazinane-4- carboxamide 1-oxide A solution of 4-({[1-({[5-({3-[(3-methyl-2-furoyl)amino]phenyl}ethynyl)pyr idin-3- yl]carbonyl}imino)-1-oxido-1 λ ⁴ ,4-thiazinan-4-yl]carbonyl}amino)butanoic acid (Example 7) 20  (65 mg, 0.11 mmol, 1 eq) and DL-3-pyrrolidinol (43.6 mg, 5 eq) in DMF (1 mL) at 0 °C was treated with 1-hydroxy-benzotriazole hydrate (25.2 mg, 1.5 eq), DIPEA (0.14 mL, 7 eq), and BOP (73 mg, 1.5 eq). The reaction mixture was stirred at 0 °C for 30 minutes, and it was then poured into aq NH ₄ Cl. The reaction mixture was extracted with EtOAc. The organic layer was washed with a combination of saturated aq NaHCO ₃ and brine (1X), brine (1X), and lastly dried 32 

with anhydrous Na ₂ SO ₄ . The residue was purified by gradient column chromatography (from neat EtOAc to MeOH-EtOAc 1:5) to give the title compound as white solid ( 39 mg ,53%). 1H NMR (DMSO-d ₆ ) δ: 10.21 (s, 1H), 9.12 (d, J = 2.0 Hz, 1H), 8.93 (d, J = 2.2 Hz, 1H), 8.44 (t, 5  J = 2.1 Hz, 1H), 8.13 (t, J = 1.6 Hz, 1H), 7.78 - 7.83 (m, 2H), 7.39 - 7.43 (m, 1H), 7.34 (dt, J = 7.6, 1.1 Hz, 1H), 6.91 (t, J = 4.9 Hz, 1H), 6.61 (d, J = 1.5 Hz, 1H), 4.87 - 4.98 (m, 1H), 4.20 - 4.31 (m, 1H), 4.09 (d, J = 16.1 Hz, 2H), 3.77 - 3.82 (m, 2H), 3.62 (dd, J = 13.6, 9.4 Hz, 2H), 3.35 - 3.52 (m, 4H), 3.20 - 3.30 (m, 2H), 3.07 (q, J = 5.9 Hz, 2H), 2.35 (s, 3H), 2.18 - 2.28 (m, 2H), 1.63 - 1.93 (m, 4H).

10 

Example 10

N-{4-[(2, - - - - - - - - - - furoyl)amino]phenyl}ethynyl)pyridin-3-yl]carbonyl}imino)-1 λ ⁴ ,4-thiazinane-4- 15  carboxamide 1-oxide In a manner similar to that described in Example 9, a solution of 4-({[1-({[5-({3-[(3- methyl-2-furoyl)amino]phenyl}ethynyl)pyridin-3-yl]carbonyl}i mino)-1-oxido-1 λ ⁴ ,4-thiazinan- 4-yl]carbonyl}amino)butanoic acid and 3-aminopropane-1,2-diol were converted to the title compound. 20  ¹ H NMR (DMSO-d ₆ ) δ: 10.21 (s, 1H), 9.12 (d, J = 2.0 Hz, 1H), 8.93 (d, J = 2.2 Hz, 1H), 8.44 (t, J = 2.1 Hz, 1H), 8.13 (t, J = 1.6 Hz, 1H), 7.76 - 7.83 (m, 3H), 7.39 - 7.43 (m, 1H), 7.34 (d, J = 7.8 Hz, 1H), 6.90 (t, J = 5.1 Hz, 1H), 6.61 (d, J = 1.5 Hz, 1H), 4.72 (d, J = 4.9 Hz, 1H), 4.50 (t, J = 5.9 Hz, 1H), 4.06 - 4.12 (m, 2H), 3.77 - 3.83 (m, 2H), 3.61 (dd, J = 13.4, 9.8 Hz, 2H), 3.44 - 3.52 (m, 3H), 3.26 (dtd, J = 10.5, 5.5, 5.3 Hz, 2H), 3.18 (ddd, J = 13.3, 5.6, 5.5 Hz, 1H), 3.01 - 3.07

33 

(m, 2H), 2.93 - 2.99 (m, 1H), 2.35 (s, 3H), 2.11 (t, J = 7.5 Hz, 2H), 1.65 (dt, J = 14.5, 7.3 Hz, 2H) Example 11

5  Ethyl ({[1-({[5- - - - - - - carbonyl}imino)- 1-oxido-1 λ ⁴ ,4-thiazinan-4-yl]carbonyl}amino)acetate In a manner similar to that described in Example 5, 5-({3-[(3-methyl-2- furoyl)amino]phenyl}ethynyl)-N-(1-oxido-1 λ ⁴ ,4-thiazinan-1-ylidene)nicotinamide and ethyl 2- isocyanatoacetate were converted to the title compound. 10  ¹ H NMR (DMSO-d ₆ ) δ: 10.21 (s, 1H), 9.12 (d, J = 2.0 Hz, 1H), 8.93 (d, J = 2.1 Hz, 1H), 8.45 (t, J = 2.0 Hz, 1H), 8.13 (s, 1H), 7.78 - 7.83 (m, 2H), 7.39 - 7.47 (m, 2H), 7.34 (d, J = 7.7 Hz, 1H), 6.61 (d, J = 1.6 Hz, 1H), 4.05 - 4.14 (m, 4H), 3.81 - 3.87 (m, 2H), 3.78 (d, J = 5.7 Hz, 2H), 3.65 (dd, J = 13.3, 9.7 Hz, 2H), 3.44 - 3.51 (m, 2H), 2.35 (s, 3H), 1.17 - 1.21 (m, 3H) Example 12

15  ({[1-({[5-({3-[(3- - - - - bonyl}imino)-1- oxido-1 λ ⁴ ,4-thiazinan-4-yl]carbonyl}amino)acetic acid In a manner similar to that described in Example 7, ethyl ({[1-({[5-({3-[(3-methyl-2- furoyl)amino]phenyl}ethynyl)pyridin-3-yl]carbonyl}imino)-1-o xido-1 λ ⁴ ,4-thiazinan-4- 20  yl]carbonyl}amino)acetate is converted to the title compound.

34 

¹ H NMR (DMSO-d ₆ ) δ: 10.21 (s, 1H), 9.12 (d, J = 2.1 Hz, 1H), 8.93 (d, J = 2.1 Hz, 1H), 8.45 (t, J = 2.0 Hz, 1H), 8.13 (t, J = 1.6 Hz, 1H), 7.82 (d, J = 1.5 Hz, 1H), 7.78 - 7.81 (m, 1H), 7.39 - 7.43 (m, 1H), 7.34 (dt, J = 7.6, 1.1 Hz, 1H), 6.99 (br. s., 1H), 6.61 (d, J = 1.5 Hz, 1H), 4.07 - 4.14 5  (m, 2H), 3.84 (dd, J = 11.6, 2.8 Hz, 2H), 3.62 (dd, J = 13.6, 9.9 Hz, 2H), 3.48 - 3.56 (m, 4H), 2.35 (s, 3H) Example 13

tert-Butyl 1-({[6- - - - - - - pyridin-3- 10  yl]carbonyl}imino)-1 λ ⁴ ,4-thiazinane-4-carboxylate 1-oxide In a manner s le 1, tert-butyl 1-imino-1 λ ⁴ ,4-thiazinane-4- carboxylate 1-oxide and 6-amino-5-((3-(3-methylfuran-2-carboxamido)phenyl)ethynyl)ni cotinic acid are converted to the title compound.

1H NMR (DMSO-d ₆ ) δ: 10.13 (s, 1 H), 8.60 (d, J = 1.5 Hz, 1H), 8.09 (s, 2H), 7.81 (s, 1H), 7.74 15  (d, J = 7.6 Hz, 1H), 7.32 - 7.45 (m, 2H), 7.04 (br. s., 2H), 6.61 (s, 1H), 3.95 - 4.06 (m, 2H), 3.70 - 3.82 (m, 2H), 3.46 - 3.67 (m, 4H), 2.35 (s, 3H), 1.43 (s, 9H Example 14

6-Amino-5-({3-[(3-me - - - - - ido-1 λ ⁴ ,4-thiazinan-1- 20  ylidene)nicotinamide 35 

In a manner similar to that described in Example 2, tert-butyl 1-({[6-amino-5-({3-[(3- methyl-2-furoyl)amino]phenyl}ethynyl)pyridin-3-yl]carbonyl}i mino)-1 λ ⁴ ,4-thiazinane-4- carboxylate 1-oxide was converted to the title compound.

1H NMR (DMSO-d ₆ ) δ: 10.13 (s, 1H), 8.59 (d, J = 2.3 Hz, 1H), 8.08 (t, J = 1.8 Hz, 2H), 7.81 (d, 5  J = 1.6 Hz, 1H), 7.74 (ddd, J = 8.4, 1.5, 1.2 Hz, 1H), 7.40 - 7.44 (m, 1H), 7.34 - 7.39 (m, 1H), 7.01 (br. s., 2H), 6.61 (d, J = 1.6 Hz, 1H), 3.68 (dt, J = 13.6, 2.4 Hz, 2H), 3.19 - 3.30 (m, 4H), 2.96 - 3.04 (m, 2H), 2.42 - 2.47 (m, 1H), 2.35 (s, 3H) Example 15

10  1-({[6-Amino-5-({3-[ - - - n-3- yl]carbonyl}imino)-1 λ ⁴ ,4-thiazinane-4-carboxamide 1-oxide In a manner similar to that described in Example 5, 6-amino-5-({3-[(3-methyl-2- furoyl)amino]phenyl}ethynyl)-N-(1-oxido-1 λ ⁴ ,4-thiazinan-1-ylidene)nicotinamide and isocyanatotrimethylsilane were converted to the title compound. 15  ¹ H NMR (DMSO-d ₆ ) δ: 10.13 (s, 1H), 8.60 (d, J = 2.2 Hz, 1H), 8.08 - 8.11 (m, 2H), 7.81 (d, J = 1.2 Hz, 1H), 7.74 (d, J = 7.8 Hz, 1H), 7.40 - 7.44 (m, 1H), 7.34 - 7.39 (m, 1H), 7.03 (br. s., 2H), 6.61 (d, J = 1.5 Hz, 1H), 6.33 (s, 2H), 4.00 - 4.07 (m, 2H), 3.70 - 3.77 (m, 2H), 3.52 - 3.60 (m, 2H), 3.37 - 3.45 (m, 2H), 2.35 (s, 3H) Example 16

20 

36 

  tert-butyl 1-({[6-Amino-5-({3-[(2-fluoro-5-methylbenzoyl)amino]phenyl}e thynyl)pyridin-3- yl]carbonyl}imino)-1 λ ⁴ ,4-thiazinane-4-carboxylate 1-oxide In a manner similar to that describe in Example 1, tert-butyl 1-imino-1 λ ⁴ ,4-thiazinane-4- carboxylate 1-oxide and 6-amino-5-((3-(2-fluoro-5-methylbenzamido)phenyl)ethynyl)nic otinic 5  acid are converted to the title compound.

1H NMR (DMSO-d ₆ ) δ: 10.46 (s, 1H), 8.60 (d, J = 2.2 Hz, 1H), 8.09 (d, J = 2.2 Hz, 1H), 8.02 (s, 1H), 7.68 (d, J = 7.9 Hz, 1H), 7.43 - 7.50 (m, 2H), 7.36 - 7.42 (m, 2H), 7.22 - 7.26 (m, 1H), 7.05 (br. s., 2H), 3.97 - 4.01 (m, 2H), 3.73 - 3.79 (m, 2H), 3.61 (br. s., 2H), 3.48 - 3.55 (m, 2H), 2.35 (s, 3H), 1.42 (s, 9H) 10  Example 17

6-Amino-5-({3-[(2-fluoro-5-methylbenzoyl)amino]phenyl}ethyny l)-N-(1-oxido-1 λ ⁴ ,4- thiazinan-1-ylidene)nicotinamide 15  In a manner similar to that described in Example 2, tert-butyl 1-({[6-amino-5-({3-[(2- fluoro-5-methylbenzoyl)amino]phenyl}ethynyl)pyridin-3-yl]car bonyl}imino)-1 λ ⁴ ,4-thiazinane- 4-carboxylate 1-oxide is converted to the title compound.

1H NMR (DMSO-d ₆ ) δ: 10.46 (s, 1H), 8.59 (d, J = 2.2 Hz, 1H), 8.08 (d, J = 2.2 Hz, 1H), 8.02 (s, 1H), 7.68 (d, J = 7.9 Hz, 1H), 7.48 (dd, J = 6.6, 1.6 Hz, 1H), 7.44 - 7.46 (m, 1H), 7.36 - 7.42 (m, 20  2H), 7.22 - 7.26 (m, 1H), 7.03 (br. s., 2H), 3.68 (ddd, J = 13.7, 2.5, 2.3 Hz, 2H), 3.21 - 3.31 (m, 4H), 3.01 (ddd, J = 13.6, 9.0, 1.8 Hz, 2H), 2.57 (br. s., 1H), 2.35 (s, 3H) Example 18

37 

1-({[6-Amino-5-({3- - - - l)pyridin-3- yl]carbonyl}imino)-1 λ ⁴ ,4-thiazinane-4-carboxamide 1-oxide In a manner similar to that described in Example 5, 6-amino-5-({3-[(2-fluoro-5- 5  methylbenzoyl)amino]phenyl}ethynyl)-N-(1-oxido-1 λ ⁴ ,4-thiazinan-1-ylidene)nicotinamide and isocyanatotrimethylsilane are converted to the title compound.

1H NMR (DMSO-d ₆ ) δ: 10.46 (s, 1H), 8.60 (d, J = 2.2 Hz, 1H), 8.10 (d, J = 2.2 Hz, 1H), 8.02 (s, 1H), 7.68 (d, J = 7.9 Hz, 1H), 7.48 (dd, J = 6.7, 1.8 Hz, 1H), 7.44 - 7.47 (m, 1H), 7.36 - 7.42 (m, 2H), 7.24 (dd, J = 9.9, 8.7 Hz, 1H), 7.04 (br. s., 2H), 6.32 (s, 2H), 4.00 - 4.06 (m, 2H), 3.71 - 10  3.76 (m, 2H), 3.57 (dd, J = 13.1, 9.2 Hz, 2H), 3.38 - 3.44 (m, 2H), 2.35 (s, 3H) Example 19

5-({3-[(3-methyl-2-furoyl)amino]phenyl}ethynyl)-N-(4-oxido-1 ,4 λ ⁴ -oxathian-4- 15  ylidene)nicotinamide

In a manner similar to that described herein, 5-iodo-N-(4-oxido-1,4λ ⁴ -oxathian-4- ylidene)nicotinamide and 3-methyl-furan-2-carboxylic acid (3-ethynyl-phenyl)-amide were converted to the title compound.

1H NMR (DMSO-d ₆ ) δ: 10.21 (s, 1H), 9.13 (d, J = 2.1 Hz, 1H), 8.94 (d, J = 2.1 Hz, 1H), 8.44 (t, 20  J = 2.1 Hz, 1H), 8.13 (t, J = 1.8 Hz, 1H), 7.82 (d, J = 1.5 Hz, 1H), 7.78 - 7.81 (m, 1H), 7.40 - 7.43 (m, 1H), 7.34 (dt, J = 7.6, 1.2 Hz, 1H), 6.61 (d, J = 1.5 Hz, 1H), 4.16 - 4.20 (m, 2H), 3.96 - 4.00 (m, 2H), 3.91 (dt, J = 14.2, 2.6 Hz, 2H), 3.65 - 3.70 (m, 2H), 2.35 (s, 3H) 38 

Preparation 4

5  6-Amino-5-iodonicotinic acid

A mixture of methyl 6-amino-5-iodonicotinate, (2.78 g, 10 mmol, 1 eq) and potassium hydroxide (2.8 g, 5 eq) in THF/H ₂ O (120 mL, 3:1) was heated at 50 ^° C for 48 hours. The reaction was then cooled to room temperature and concentrated HCl was drop wise added until a pH around 3~4 was achieved. The solution was concentrated and the resulting precipitate was 10  collected by filtration to give the title compound as a slightly brown solid (1.77 g.)

1H NMR (DMSO-d ₆ ) δ: 12.64 (br. s., 1H), 8.47 (d, J = 2.1 Hz, 1H), 8.25 (d, J = 1.8 Hz, 1H), 6.88 (br. s., 2H) Preparation 5

15  6-amino-5-iodo-N-(4-oxido-1,4 λ ⁴ - - - otinamide To a solution of 1,4-oxathiane (510 mg, 3.21 mmol, 1.05 eq) in anhydrous DMF (8 mL) was added 6-amino-5-iodonicotinic acid (806 mg, 1.0 eq), diisopropylethylamine (1.1 mL, 2 eq), and BOP (1.484 g, 1.1 eq). The reaction mixture was heated at 60 ^° C for 20 hours and then partitioned between EtOAc and aq NH ₄ Cl. The organic layer was separated, washed further with 20  saturated aq NaHCO ₃ (1X), brine (1X), and dried with anhydrous Na ₂ SO ₄ overnight. The upper solution layer was decanted, concentrated, and the brown oily reside was subject to column chromatography (EtOAc-Hex 1:5 to 3:1). Concentration of the product eluting fractions gave the title compound as white solid (889 mg, 77%). 39 

¹ H NMR (DMSO-d ₆ ) δ: 8.57 (d, J = 2.1 Hz, 1H), 8.35 (d, J = 2.1 Hz, 1H), 6.78 (br. s., 2H), 4.10 - 4.15 (m, 2H), 3.91 (ddd, J = 12.6, 8.5, 2.1 Hz, 2H), 3.79 - 3.84 (m, 2H), 3.55 - 3.60 (m, 2H) Example 20

5  6-amino-5-({3-[(3-methyl- 4-oxido-1,4λ ⁴ -oxathian-4- ylidene)nicotinamide

To a solution of 6-amino-5-iodo-N-(4-oxido-1,4λ ⁴ -oxathian-4-ylidene)nicotinamide (57.2 mg, 0.15 mmol, 1.0 eq) and 3-methyl-furan-2-carboxylic acid (3-ethynyl-phenyl)-amide (43.9 mg, 1.3 eq) in anhydrous DMF (1 mL) under nitrogen atmosphere was added

10  bis(triphenylphosphine)palladium(II) dichloride (10.5 mg, 0.1 eq), triethylamine (0.11 mL, 5.0 eq), and copper(I) iodide (5.7 mg, 0.2 eq). The reaction mixture was stirred at RT for 15 minutes and then partitioned between saturated aq NaHCO ₃ and EtOAc. The organic layer was isolated, washed further with aqueous NH ₄ Cl, brine, and dried with anhydrous Na ₂ SO ₄ . The organic phase was decanted, dried and concentrated. The residue was subject to a gradient chromatography 15  (EtOAc-Hexanes from 1:9 to neat EtOAc). Concentration of the product eluting fractions gave the title compound as white solid (56 mg).

1H NMR (DMSO-d ₆ ) δ: 10.13 (s, 1H), 8.61 (d, J = 2.1 Hz, 1H), 8.08 - 8.10 (m, 2H), 7.81 (d, J = 1.8 Hz, 1H), 7.72 - 7.75 (m, 1H), 7.41 - 7.43 (m, 1H), 7.35 - 7.39 (m, 1H), 7.04 (br. s., 2H), 6.60 (d, J = 1.5 Hz, 1H), 4.12 - 4.17 (m, 2H), 3.93 (ddd, J = 12.5, 8.7, 2.1 Hz, 2H), 3.82 - 3.86 (m, 20  2H), 3.56 - 3.61 (m, 2H), 2.35 (s, 3H) Example 21

40 

6-amino-5-({3-[(2-fluoro-5-methylbenzoyl)amino]phenyl}eth ynyl)-N-(4-oxido-1,4 λ ⁴ - oxathian-4-ylidene)nicotinamide

In a manner similar to that described in the examples above, 6-amino-5-iodo-N-(4-oxido- 1,4λ ⁴ -oxathian-4-ylidene)nicotinamide and N-(3-ethynylphenyl)-2-fluoro-5-methylbenzamide 5  were converted to the title compound.

1H NMR (DMSO-d ₆ ) δ: 10.46 (s, 1H), 8.61 (d, J = 2.1 Hz, 1H), 8.10 (d, J = 2.1 Hz, 1H), 8.03 (s, 1H), 7.68 (d, J = 8.2 Hz, 1H), 7.44 - 7.49 (m, 2H), 7.36 - 7.42 (m, 2H), 7.24 (dd, J = 9.8, 8.7 Hz, 1H), 7.06 (br. s., 2H), 4.12 - 4.16 (m, 2H), 3.93 (ddd, J = 12.5, 8.7, 1.9 Hz, 2H), 3.81 - 3.86 (m, 2H), 3.56 - 3.61 (m, 2H), 2.35 (s, 3H) 10  Example 22

6-amino-5-[(3-{[(2-fluo l)ethynyl]-N-(4-oxido-1,4 λ ⁴ -oxathian-4-ylidene)nicotinamide

In a manner similar to that described in the examples above, 6-amino-5-iodo-N-(4-oxido- 15  1,4λ ⁴ -oxathian-4-ylidene)nicotinamide and 3-ethynyl-N-(2-fluoro-5-methylphenyl)benzamide were converted to the title compound.

1H NMR (DMSO-d ₆ ) δ: 10.15 (s, 1 H), 8.62 (d, J = 2.3 Hz, 1H), 8.27 (s, 1H), 8.12 (d, J = 2.3 Hz, 1H), 7.96 (d, J = 7.6 Hz, 1H), 7.91 (d, J = 7.9 Hz, 1H), 7.58 (t, J = 7.8 Hz, 1H), 7.41 (dd, J = 7.3, 1.5 Hz, 1H), 7.18 (dd, J = 10.1, 8.7 Hz, 1H), 7.14 (br. s., 2H), 7.06 - 7.09 (m, 1H), 4.12 - 4.17 20  (m, 2H), 3.91 - 3.96 (m, 2H), 3.83 (ddd, J = 14.2, 2.6, 2.3 Hz, 2H), 3.57 - 3.62 (m, 2H), 2.31 (s, 3H) Preparation 6

N-[4-chloro-3-(trifluoromethyl)phenyl]-3-iodobenzamide To the mixture of 3-iodobenzoic acid (1.28 g, 5.04 mmol, 1 eq) and 4-chloro-3- (trifluoromethyl)-aniline (1.48 g, 1.5 eq) in anhydrous DMF (15 mL) was added catalytic amount of DMAP (123.1 mg, 0.2 eq) and EDCI (1.16 g, 1.2 eq). The reaction was stirred at 70 ^° C for 20 5  hours. It was then partitioned between EtOAc and saturated aq NaHCO ₃ . The organic layer was further washed with aqueous NH4Cl, brine and dried with anhydrous sodium sulfate. The organic layer was decanted, dried and concentrated. The residue was subject to a gradient column chromatography (from neat Hex to EtOAc-Hex 1:25). The product fractions were collected, concentrated, and the solid residue was triturated with EtOAc-Hex (1:25) and the solid 10  which formed was collected and dried to give that title compound as a white solid (1.996 g, 93%).

1H NMR (DMSO-d ₆ ) δ: 10.68 (s, 1H), 8.31 - 8.34 (m, 2H), 8.10 (dd, J = 8.8, 2.3 Hz, 1H), 7.96 - 8.00 (m, 2H), 7.73 (d, J = 8.8 Hz, 1H), 7.37 (t, J = 7.8 Hz, 1H) Preparation 7

15  6-amino-N-(4-oxido-1,4λ ⁴ -oxa - - - - lsilyl)ethynyl]nicotinamide To a reaction vessel containing 6-amino-5-iodo-N-(4-oxido-1,4λ ⁴ -oxathian-4- ylidene)nicotinamide, (570 mg, 1.50 mmol, 1 eq) and trimethylsilylacetylene (1.24 mL, 6 eq) in anhydrous DMF (4 mL) under anhydrous nitrogen atmosphere was added triethylamine (1.67 20  mL, 8 eq), bis(triphenylphosphine)palladium(II) dichloride (105 mg, 0.1 eq), and copper(I)

iodide (57.1 mg, 0.2 eq). The reaction mixture was stirred at room temperature for 15 minutes and then partitioned between saturated aq NaHCO ₃ and EtOAc. The organic layer was separated, washed with aq NH ₄ Cl (1X) and brine (1X), followed by drying with anhydrous Na ₂ SO ₄ . The organic phase was decanted, concentrated, and the brown oily residue was subject to a gradient 25  column chromatography (EtOAc-Hex 1:10 to 5:1). Concentration of the product eluting

fractions gave the title compound as white foam ( 525 mg). 42 

  Example 23

6-amino-5-{[3-({[4-chlo onyl)phenyl]ethynyl}-N- (4-oxido-1,4 λ ⁴ -oxathian-4-ylidene)nicotinamide

5  To 6-amino-N-(4-oxido-1,4λ ⁴ -oxathian-4-ylidene)-5- [(trimethylsilyl)ethynyl]nicotinamide, (71 mg, 0.2 mmol, 1 eq) and N-[4-chloro-3- (trifluoromethyl)phenyl]-3-iodobenzamide (112 mg, 1.3 eq) in anhydrous DMF (2 mL) under nitrogen atmosphere were added copper(I) iodide (8.0 mg, 0.2 eq), triethylamine (0.14 mL, 5 eq), and bis(triphenylphosphine)palladium(II) dichloride (14 mg, 0.1 eq), followed by the final 10  addition of tetrabutylammonium fluoride (1.0 M in THF; 0.22 mL, 1.1 eq). The reaction was stirred at ambient temperature for 15 minutes. Then it was partitioned between EtOAc and aq NH ₄ Cl. The organic layer was isolated, washed with saturated aq NaHCO ₃ , and brine, and dried with anhydrous Na ₂ SO ₄ . The organic layer was decanted, dried and concentrated. The residue was subject to a gradient column chromatography (EtOAc-Hex 1:5 to 1:2) which was followed 15  by another gradient column chromatography (from neat CHCl ₃ to MeOH-CHCl ₃ 1:50). The

product fractions were collected, concentrated. The solid which formed while concentrating was collected by filtration and dried to give the title compound as a yellow solid ( 58 mg).

1H NMR (DMSO-d ₆ ) δ: 10.73 (s, 1H), 8.63 (d, J = 2.3 Hz, 1H), 8.37 (d, J = 2.6 Hz, 1H), 8.29 (t, J = 1.5 Hz, 1H), 8.11 - 8.15 (m, 2H), 7.95 (dd, J = 16.9, 7.8 Hz, 2H), 7.74 (d, J = 8.8 Hz, 1H), 20  7.61 (t, J = 7.8 Hz, 1H), 7.15 (br. s., 2H), 4.12 - 4.17 (m, 2H), 3.91 - 3.96 (m, 2H), 3.83 (dt, J = 14.3, 2.7 Hz, 2H), 3.57 - 3.62 (m, 2H) Example 24

43 

6-amino-5-[(3-{[(5-tert-butylisoxazol-3-yl)amino]carbonyl }phenyl)ethynyl]-N-(4-oxido-1,4 λ ⁴ -oxathian-4-ylidene)nicotinamide

In a manner similar to that described in Example 23, 6-amino-N-(4-oxido-1,4λ ⁴ -oxathian- 5  4-ylidene)-5-[(trimethylsilyl)ethynyl]nicotinamide and N-(5-(tert-butyl)isoxazol-3-yl)-3- iodobenzamide were converted to the title compound.

1H NMR (DMSO-d ₆ ) δ: 11.41 (s, 1H), 8.63 (d, J = 2.3 Hz, 1H), 8.31 (t, J = 1.6 Hz, 1H), 8.12 (d, J = 2.1 Hz, 1H), 7.99 (dt, J = 7.9, 1.4 Hz, 1H), 7.91 (dt, J = 7.6, 1.2 Hz, 1H), 7.58 (t, J = 7.8 Hz, 1H), 7.13 (br. s., 2H), 6.73 (s, 1H), 4.12 - 4.17 (m, 2H), 3.94 (ddd, J = 12.5, 8.7, 2.1 Hz, 2H), 10  3.81 - 3.85 (m, 2H), 3.57 - 3.62 (m, 2H), 1.33 (s, 9H) Example 25

6-amino-5-[(3-{[(3- -N-(4-oxido-1,4 λ ⁴ - oxathian-4-ylidene)nicotinamide

15  In a manner similar to that described in Example 23, 6-amino-N-(4-oxido-1,4λ ⁴ -oxathian- 4-ylidene)-5-[(trimethylsilyl)ethynyl]nicotinamide and 3-iodo-N-(3-methoxyphenyl)benzamide were converted to the title compound.

1H NMR (DMSO-d ₆ ) δ: 10.30 (s, 1H), 8.62 (d, J = 2.3 Hz, 1H), 8.26 (t, J = 1.5 Hz, 1H), 8.12 (d, J = 2.1 Hz, 1H), 7.94 (ddd, J = 7.8, 1.3, 1.2 Hz, 1H), 7.90 (dt, J = 7.6, 1.2 Hz, 1H), 7.58 (t, J = 20  7.8 Hz, 1H), 7.47 (t, J = 2.2 Hz, 1H), 7.39 (dd, J = 8.1, 1.0 Hz, 1H), 7.26 (t, J = 8.1 Hz, 1H), 7.14 (br. s., 2H), 6.70 (dd, J = 8.2, 2.1 Hz, 1H), 4.12 - 4.17 (m, 2H), 3.93 (ddd, J = 12.5, 8.5, 1.9 Hz, 2H), 3.83 (dt, J = 14.3, 2.7 Hz, 2H), 3.76 (s, 3H), 3.57 - 3.62 (m, 2H). Biological data for the compounds of the present invention was generated by use of the following assays. 25  44 

VEGFR2 Kinase Assay Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS + 0.05% Tween-20 5  (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50mM Hepes buffer pH 7.4, 20mM MgCl ₂ , 0.1 mM MnCl ₂ and 0.2 mM Na ₃ VO ₄ ). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 10  20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, CA). Following a 15 minute incubation at 30 ⁰ C., the reactions were washed 2 mls per well PBS-T. 100μl of a monoclonal anti-phosphotyrosine antibody- peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.

Following a 2 mls per well wash with PBS-Tween-20, 100μl of O-Phenylenediamine

15  Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100µl of 2.5N H ₂ SO ₄ to each well and read using a microplate ELISA reader set at 492 nm. IC ₅₀ values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction 20  of blank values. VEGFR2 Cellular Assay Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 25  384-well fibronectin coated black- walled plates overnight @ 37 ^o C/5%CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 ^o C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF ₁₆₅ stimulation (10 ng/mL). Changes in fluorescence at 516 30  nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were

45 

generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples. IC ₅₀ values for test compounds were calculated from % inhibition of VEGF stimulated responses in the absence of inhibitor. PDGFRβ Kinase Assay 5  Biochemical PDGFRβ kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg of poly-Glu-Tyr (4:1) in 10mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS + 0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes 10  containing 36 μM ATP in kinase buffer (50mM Hepes buffer pH 7.4, 20mM MgCl ₂ , 0.1 mM MnCl ₂ and 0.2 mM Na ₃ VO ₄ ). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain PDGFR-b protein (Millipore). Following a 60 minute incubation at 30 ⁰ C., the reactions were washed 2 mls 15  per well PBS-T. 100μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100µl 20  of 2.5N H ₂ SO ₄ to each well and read using a microplate ELISA reader set at 492 nm. IC ₅₀ values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values. PDGFRβ Cellular Assay Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen 25  for inhibitors of PDGF-induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. NHDF-Ad (Normal Human Dermal Fibroblasts, Adult; Lonza) were seeded in 384-well fibronectin coated black- walled plates overnight @ 37 ^° C/5%CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 ^° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with 46 

test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by PDGF-BB stimulation (30 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug 5  treated samples. IC ₅₀ values for test compounds were calculated from % inhibition of PDGF-BB stimulated responses in the absence of inhibitor. The biological results for the compounds of formula I are shown in Table 2 below.

47 

  ⁾

P

( ^A

S

7 _U

5

9 ₃

1

)

  4 ⁸

  ⁾

P

( ^A

S

7 _U

5

9 ₃

1

β _{e )}

  4 ⁹

  ⁾

P

( ^A

S

7 _U

5

9 ₃

1

)

  5 ⁰

  ⁾

P

( ^A

S

7 _U

5

9 ₃

1

)

  5 ¹

  ⁾

P

( ^A

S

7 _U

5

9 ₃

1

)

  5 ²

  ⁾

P

( ^A

S

7 _U

5

9 ₃

1

  5 ³

  ⁾

P

( ^A

S

7 _U

3 ₅

1 ⁹

  5 ⁴

Examples 3, 11 , 13, 16 and 17 are most preferred compounds of formula I, as they have the greatest potency at both VEGFR2 and PDGFR receptors.

It is noted that the compounds of Examples 19 through 25 have activity at both the VEGF and PDGF receptors.

The compounds of Examples 19 and 20 have the best activity at the VEGFR2 Receptor of the compounds of formula II.

The compounds of Examples 22 and 24 have the best activity at the PDGFRP Receptor of the compounds of formula II.

The present invention is not to be limited in scope by the exemplified embodiments which are intended as illustrations of single aspects of the invention only. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall 5  within the scope of the appended claims. All references cited herein are hereby incorporated by reference in their entirety. Also, the compounds of the present invention may be tested by the various in-vitro and in-vivo assays disclosed in such references to demonstrate the claimed utilities.

56